Stocks and Shares
The latest news, updates and opinions on Stocks and Shares from the expert team here at MoneyWeek
Explore Stocks and Shares
-
Share tips 2025: this week’s top picks
Share tips Share tips 2025: MoneyWeek’s roundup of the top picks this week – here’s what the experts think you should buy
By Kalpana Fitzpatrick Last updated
Share tips -
Magnificent 7: how will tariffs impact big tech stocks?
The Magnificent 7 stock price has seesawed as uncertainty over Trump’s tariff regime has seen investors look for certainty over trade policy.
By Dan McEvoy Last updated
-
Should you invest in Tesla?
Tesla’s share price has tumbled around 48% from its all-time high in December. Should you buy the dip or steer clear?
By Katie Williams Last updated
-
Can a rebrand save WH Smith?
Opinion WH Smith's high-street shops have had their day and a change of owner is unlikely to turn things around, says Matthew Lynn
By Matthew Lynn Published
Opinion -
Nvidia shares slump as Trump tightens export controls
Confirmation that its H20 AI chips will need a license to be exported to China has hurt Nvidia’s shares, after a volatile two weeks following the announcement of sweeping tariffs on US imports
By Dan McEvoy Last updated
-
Anne Wojcicki: the daring 23andMe CEO who reached too far
Profile Anne Wojcicki dreamed of a revolution in personal genomics and medicine and set up 23andMe in 2006. Its collapse into bankruptcy provides a cautionary tale
By Jane Lewis Published
Profile -
The star small and mid-cap stocks income investors have overlooked
Opinion Thomas Moore, senior investment director, Aberdeen, highlights three company stocks as he shares where he would put his money
By Thomas Moore Published
Opinion -
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge Published
-
Greggs’ recipe for success on the high street
Greggs grew from a shop founded in Newcastle after the war into a national treasure. Profits will continue to roll in for patient investors, says Jamie Ward
By Jamie Ward Published